AOD9604

Name: AOD9604
Brand: Lyochem
SKU: aod9604

Modified HGH fragment 176–191 (anti-obesity drug candidate)

≥ 99.0%CAS 221231-10-3GH-Axis Peptides

Overview

AOD9604 is a modified analog of the C-terminal 176-191 fragment of human growth hormone, developed at Monash University in Australia as a lipolytic / anti-obesity research and clinical-development candidate. The molecule consists of the native HGH(176-191) sequence with an additional N-terminal tyrosine residue added to support iodination for tracking studies during preclinical development. AOD9604 retains the lipolytic activity associated with the HGH C-terminal region (the segment hypothesized to drive fat-cell lipolysis through a non-GH-receptor mechanism) while lacking the broader anabolic effects mediated by the full-length HGH molecule's central regions. The molecule advanced through Phase 2 clinical development for obesity but did not achieve regulatory approval; it has since transitioned to research-use and dietary-supplement markets in some jurisdictions. Lyochem supplies lyophilized AOD9604 at ≥99.0% HPLC purity with batch-specific COA. The N-terminal tyrosine modification distinguishes AOD9604 from the unmodified HGH Fragment 176-191, buyers should be explicit about which they want at order placement. Three standard fill sizes (2, 5, 10 mg) cover typical research and compounding workflows.

Who buys this, and why

GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.

Primary buyer fit: academic and contract research laboratories and research laboratories that have validated this peptide into their workflow.

Specifications

CAS: 221231-10-3
Appearance: White lyophilized powder
Purity (HPLC): ≥ 99.0%
Common vial sizes: 2 mg, 5 mg, 10 mg
MOQ: On request
Lead time: 10–18 days
Storage: -20°C, protect from light

Documentation available on request

Lot-specific Certificate of Analysis (CoA)
RP-HPLC chromatogram with peak integration
ESI-MS identity confirmation (±0.5 Da)
Sequence verification by LC-MS/MS
Water content by Karl Fischer
SDS / MSDS
Counter-ion analysis (acetate vs TFA)
Stability at −20 °C across 12 months
Solubility in BAC water / PBS reconstitution

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.

Frequently asked questions

Why is AOD9604 considered an 'anti-obesity drug candidate' rather than just a research peptide?▾

AOD9604 was developed at Monash University in Australia and advanced through Phase 2b clinical trials for obesity as a registered drug-development program. The trials produced modest weight-loss signals (smaller than what GLP-1 agonists have since demonstrated), and the program did not achieve regulatory approval as a finished drug. Following discontinuation of the obesity-drug program, AOD9604 transitioned to research-use and to dietary-supplement markets in some jurisdictions, where it is marketed under various brand names. The 'anti-obesity drug candidate' framing reflects the molecule's clinical-development history; buyers should not assume the molecule is an approved drug.

Is AOD9604 a GH analog, and does it activate the GH receptor?▾

AOD9604 is derived from the C-terminal region of human GH (residues 176-191) but is not a GH receptor agonist, the GH-receptor-binding region of full-length GH is in the central portion of the protein, not the C-terminal fragment. AOD9604's lipolytic activity is hypothesized to act through a separate, non-GH-receptor mechanism. This is the key pharmacological distinction from full-length recombinant HGH: AOD9604 retains the lipolytic effects associated with the C-terminal region of GH but lacks the broader anabolic and IGF-1-stimulating effects mediated by the central GH-receptor-binding region. The downstream consequence is a substantially narrower pharmacological profile than HGH.